|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.22 USD | -1.04% |
|
+0.81% | +1.90% |
| 06:08am | Pfizer Says Braftovi Combination Regimen Improves Response Rate in Metastatic Colorectal Cancer | MT |
| Jan. 10 | Pfizer announces positive results from Breakwater trial cohort 3 | RE |
Chart calendar Pfizer Inc.
Upcoming events on Pfizer Inc.
| 2026-01-22 | Ex-dividend day | Add to your calendar Google Apple ICS format |
| 2026-02-03 | Q4 2025 Earnings Release | Add to your calendar Google Apple ICS format |
| 2026-02-03 | Q4 2025 Earnings Call | Add to your calendar Google Apple ICS format |
| 2026-05-04 | Q1 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
| 2026-08-03 | Q2 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
| 2026-11-02 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
| 2027-02-01 | Q4 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
Past events on Pfizer Inc.
| Today | J.P. Morgan Healthcare Conference |
| 2025-12-16 | Q4 2026 Guidance Call |
| 2025-11-19 | Jefferies Global Healthcare Conference |
| 2025-11-10 | Business Update Call |
| 2025-11-06 | Ex-dividend day |
| 2025-11-04 | Q3 2025 Earnings Call |
| 2025-11-04 | Q3 2025 Earnings Release |
| 2025-10-20 | European Society of Medical Oncology Congress - Oral Presentation No:489MO |
| 2025-10-20 | European Society of Medical Oncology Congress - Oral Presentation No:485MO |
| 2025-10-20 | European Society of Medical Oncology Congress - Oral Presentation No:729O |
| 2025-10-19 | European Society of Medical Oncology Congress - Oral Presentation No:1329MO |
| 2025-10-19 | European Society of Medical Oncology Congress - Oral Presentation No:LBA87 |
| 2025-10-19 | European Society of Medical Oncology Congress - Oral Presentation No:LBA86 |
| 2025-10-19 | European Society of Medical Oncology Congress - Oral Presentation No:1849MO |
| 2025-10-18 | European Society of Medical Oncology Congress |
| 2025-10-17 | European Society of Medical Oncology Congress - Oral Presentation No:LBA102 |
| 2025-09-22 | Acquisition of Metsera, Inc by Pfizer Inc Call |
| 2025-08-05 | Q2 2025 Earnings Call |
| 2025-08-05 | Q2 2025 Earnings Release |
| 2025-07-25 | PD-1 x VEGF Bispecific Antibody Call |
Past dividends on Pfizer Inc.
| 2025-11-06 | Quarterly 0.43 USD |
| 2025-07-24 | Quarterly 0.43 USD |
| 2025-05-08 | Quarterly 0.43 USD |
| 2025-01-23 | Quarterly 0.43 USD |
| 2024-11-07 | Quarterly 0.42 USD |
| 2024-07-25 | Quarterly 0.42 USD |
| 2024-05-08 | Quarterly 0.42 USD |
| 2024-01-24 | Quarterly 0.42 USD |
| 2023-11-08 | Quarterly 0.41 USD |
| 2023-07-26 | Quarterly 0.41 USD |
| 2023-05-10 | Quarterly 0.41 USD |
| 2023-01-25 | Quarterly 0.41 USD |
| 2022-11-02 | Quarterly 0.4 USD |
| 2022-07-27 | Quarterly 0.4 USD |
| 2022-05-11 | Quarterly 0.4 USD |
| 2022-01-26 | Quarterly 0.4 USD |
| 2021-11-03 | Quarterly 0.39 USD |
| 2021-07-28 | Quarterly 0.39 USD |
| 2021-05-05 | Quarterly 0.39 USD |
| 2021-01-27 | Quarterly 0.39 USD |
Annual results
| Fiscal Period | December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 100 330 100 373 -0.04% | 58 496 59 105 -1.03% | 63 627 63 071 0.88% | 61 967 | 60 994 | 59 110 |
|
EBITDA Million USD | Released Forecast Spread | 42 336 44 597 -5.07% | 15 590 11 249 38.59% | 28 801 25 014 15.14% | 24 707 | 24 975 | 23 602 |
|
EBIT Million USD | Released Forecast Spread | 37 272 40 403 -7.75% | 9 300 8 509 9.3% | 21 788 20 589 5.82% | 21 253 | 21 336 | 20 225 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 34 729 39 058 -11.08% | 1 058 2 301 -54.02% | 8 023 11 544 -30.5% | 12 664 | 14 872 | 14 300 |
|
Net income Million USD | Released Forecast Spread | 31 372 33 053 -5.09% | 2 119 3 040 -30.29% | 8 031 9 732 -17.47% | 11 638 | 12 883 | 12 472 |
|
EPS USD | Released Forecast Spread | 5,47 5,85 -6.45% | 0,37 0,72 -48.44% | 1,41 1,70 -17.17% | 2,03 | 2,22 | 2,16 |
| Announcement Date | 31/01/23 | 30/01/24 | 04/02/25 | - |
Quarterly results
| Fiscal Period | September | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | 2027 Q2 | 2027 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 14 879 13 923 6.87% | 13 283 13 019 2.03% | 17 702 14 865 19.08% | 17 763 17 264 2.89% | 13 715 14 051 -2.39% | 14 653 13 531 8.29% | 16 654 16 502 0.92% | 16 912 | 13 982 | 14 501 | 16 023 | 16 407 | 13 810 | 14 505 | 16 345 |
|
EBITDA Million USD | Released Forecast Spread | 7 648 4 403 73.7% | 5 906 3 663 61.26% | 7 478 4 647 60.92% | 6 391 4 136 54.54% | 7 548 6 180 22.14% | 6 940 5 487 26.49% | 7 303 6 229 17.23% | 5 926 | 7 031 | 6 927 | 7 066 | ||||
|
EBIT Million USD | Released Forecast Spread | 5 912 3 667 61.24% | 4 175 3 346 24.78% | 7 035 3 978 76.86% | 4 672 3 357 39.18% | 5 930 4 982 19.02% | 5 315 4 410 20.51% | 5 641 4 704 19.93% | 4 205 | 5 523 | 5 381 | 6 115 | 5 236 | |||
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 3 421 2 992 14.34% | -103 2 049 -105.03% | 4 715 2 616 80.24% | -10,0 2 104 -100.48% | 2 785 3 880 -28.22% | 3 044 2 468 23.34% | 3 334 3 240 2.9% | 3 002 | |||||||
|
Net income Million USD | Released Forecast Spread | 3 115 1 951 59.69% | 41,0 1 733 -97.63% | 4 465 1 725 158.79% | 410 1 002 -59.1% | 2 967 2 913 1.86% | 2 910 2 063 41.07% | 3 541 2 334 51.72% | 2 154 | 3 121 | 3 216 | 4 030 | 2 746 | |||
|
EPS USD | Released Forecast Spread | 0,55 0,34 61.01% | 0,01 0,30 -96.67% | 0,78 0,30 160.81% | 0,07 0,20 -65.43% | 0,52 0,51 2.91% | 0,51 0,36 41.65% | 0,62 0,44 42.49% | 0,39 | 0,50 | 0,54 | 0,64 | 0,48 | |||
| Announcement Date | 01/05/24 | 30/07/24 | 29/10/24 | 04/02/25 | 29/04/25 | 05/08/25 | 04/11/25 | - | - | - | - | - | - | - | - |
| 2026-01-15 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-15 | Q3 2026 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-20 | Q3 2026 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-20 | Q4 2025 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-21 | Q4 2025 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-21 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-21 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-22 | Q3 2026 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-22 | Q3 2026 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-27 | Q3 2026 Earnings Release | Add to your calendar Google Apple ICS format |
Past sector events for Pfizer Inc.
| 2026-01-10 | December 2025 Sales and Revenue Release | |
| 2026-01-09 | December 2025 Sales and Revenue Release | |
| 2026-01-08 | December 2025 Sales and Revenue Release | |
| 2026-01-08 | Q2 2026 Earnings Release | |
| 2026-01-08 | December 2025 Sales and Revenue Release | |
| 2026-01-07 | December 2025 Sales and Revenue Release | |
| 2026-01-05 | Q3 2025 Earnings Release | |
| 2026-01-05 | December 2025 Sales and Revenue Release | |
| 2025-12-22 | Q3 2025 Earnings Release | |
| 2025-12-19 | Q2 2026 Earnings Release |
Quarterly revenue - Rate of surprise
Net sales - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PFE Stock
- Calendar Pfizer Inc.
Select your edition
All financial news and data tailored to specific country editions
















